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Multifunctional Gd-based mesoporous silica
nanotheranostic for anticancer drug delivery†
Fabio Carniato, ‡a Diego Alberti, ‡b Angelica Lapadula,bc Jonathan Martinelli,a
Ciro Isidoro, c Simonetta Geninatti Crich b and Lorenzo Tei *a
A nanosized drug delivery system based on mesoporous silica nanoparticles functionalized with highly
stable GdDOTAGA complexes, rhodamine dyes and PEG3000 molecules was synthesized. The external
side of the PEG was also functionalized with azadibenzocyclooctyne moieties in order to exploit the
bioorthogonal Cu(I)-free click chemistry targeting approach after metabolic labeling of cell-surface glycans
with azido-mannose molecules. The particles’ pores were then impregnated with the chemotherapeutic
drug mitoxantrone to add a therapeutic function to the nanosystem. The bioorthogonal targeting of the
nanotheranostic probe on mannose-treated breast cancer MCF7 and TS/A cells showed a minimal
difference between cells metabolically labeled or not. However, MRI experiments on labeled MCF7 cells
showed a significant 200% contrast enhancement with respect to untreated cells, thus confirming the high
contrast efficiency even when the cells were incubated with nanoparticles for a few minutes. Moreover,
administration of the nanoprobe to MCF7 cultures resulted in a higher cytotoxicity in comparison to the
free drug at a similar concentration, confirming the successful delivery of the drug.
1. Introduction
Theranostics is a newly emerging concept aimed at developing
imaging procedures able to provide a non-invasive in vivo
visualization of therapeutic treatments. A theranostic system
enables obtaining more accurate pharmacokinetics and drug
delivery data, such as overall biodistribution, organ delivery success
and targeting efficiency. This novel biomedical approach requires
the use of chemical species containing in the same structure both
diagnostic and therapeutic agents.1–3 A typical theranostic protocol
requires an imaging reporter able to visualize a specific biomarker
that characterizes the pathology of interest and/or is involved in the
mechanism of action of the therapeutic treatment. Thus, the
efficacy of the therapy can be determined by looking at the changes
in the imaging response of the biomarker. Among the available
imaging modalities, magnetic resonance imaging (MRI) shows
peculiar advantages over the other available techniques such as
impressive spatial resolution of soft tissues, very low invasiveness,
optimal temporal resolution and outstanding versatility. On the
other hand, the greatest disadvantage of MRI is its relatively poor
sensitivity, which requires the use of contrast agents at high
concentration in order to visualize the desired biomarker.4 This
drawback can be overcome by using nanocarriers (micelles,
liposomes, inorganic/organic nanoparticles) that, typically, are
the same cargos employed to improve the therapeutic index of
many drugs. Great efforts have been made in this direction, as
testified by the reviews and articles published in the last few
decades within this field.5–7 Various nano-devices have been
proposed for the construction of novel theranostic agents including
multifunctional nanoparticles (NPs), polymeric micelles, and lipo-
somes, often enriched with iron oxide NPs or paramagnetic metal
ions.8–11 Among them, mesoporous silica nanoparticles (MSNs) have
also been considered for the generation of a new family of nano-
formulations.12–15
Many researchers have focused their studies on the development
of MSNs optimized for controlled drug delivery. In 2001, Vallet-Regı́
et al. for the first time investigated the release of anti-inflammatory
drugs entrapped in MCM-41 pores.16 More recently, MSNs
functionalized with different drugs and decorated with different
biocompatible (i.e. phospholipid layers)17 and target molecules
(folic acid, peptides, and specific ligands)18 have been proposed
as efficient drug delivery systems.
In parallel, MSNs have also been exploited for the development
of T1 MR-enhancing hybrid materials based on gadolinium(III)
complexes anchored onto the MSN surface.19 Initial studies
reported on the anchoring of the chelates on MSNs, with different
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shapes and sizes, aimed to increase the 1H relaxivity of the system
for cell tracking and angiographic MRI applications.20 More
recently, studies in our laboratories on the anchoring of different
Gd(III) complexes on the internal or external surfaces of MSNs and
on the modification of the surface functionalities have led us to
optimize the nanoprobe, reaching very high relaxivities.19,21–23 The
final outcome is that Gd(III) chelates have to be anchored onto the
external surface of the MSNs because water diffusion inside
the pores is limited and this prevents the transfer of the para-
magnetic effect to the bulk water. A synthetic procedure for the
preparation of efficient GdDOTA-like chelates anchored onto
the MSN external surface was developed resulting in a very high
relaxivity of the system.21
Nevertheless, it must be noted that the combination in the
same nanoparticles of both drug molecules and MRI contrast
agents has marginally been explored. The few examples reported
in the literature described the preparation of hybrid organic–
inorganic MSNs containing drug molecules (e.g. doxorubicin)
and functionalized with T2-contrast agents, such as Fe2O3,
24 or
the use of the hollow space between a stable iron nanocore and
a mesoporous silica shell to load anticancer drugs and GdDTPA
molecules.25 Interestingly, Kempen et al. developed theranostic
MSNs offering both ultrasound and MRI signals to monitor the
delivery of insulin growth factor to mesenchymal stem cells.26
However, optimization of all functionalities present in the
same MSN platform, in terms of enhanced imaging contrast,
controlled drug release and selective uptake, is a challenge for
the research in the theranostic field. In particular, all these
functions in the final theranostic probe should work without
losing efficiency and, therefore, an accurate design of the
synthetic procedure is required. Some in vitro examples have
been reported showing the influence of the mutual interactions
between the drug, the Gd(III) chelates and the silica surface on
the effectiveness of the final theranostic system.27 In another
system, the selective surface functionalization of MCM-48
nanoparticles by GdDTPA-monoamide and polyethylene glycol
(PEG) molecules allowed optimization of the drug (daunorubicin)
loading and release performances, avoiding pore obstruction.28
Herein we independently functionalized the three well-defined
domains of MSNs by anchoring MRI contrast agents, a fluorescent
dye, PEG molecules and targeting groups onto the MSN surface,
and confining drug molecules inside the pores. Based on our
previous studies on Gd-functionalized MSNs,21,22 we chose
GdDOTAGA complexes (DOTAGA = (R)-2-(4,7,10-triscarboxymethyl-
1,4,7,10-tetraazacyclododec-1-yl)pentanedioic acid) as MRI agents
anchored onto the silica surface. In fact, GdDOTAGA is a thermo-
dynamically stable, kinetically inert, mononegative GdDOTA-like
system with one inner-sphere water molecule with an optimal water
exchange rate (tM = 1/kex = ca. 100 ns)
29 that allows obtaining high
relaxivities when attached to the silica surface. Then, PEG molecules
were grafted at the outer surface of MSNs to improve their colloidal
stability under physiological conditions, as well as bio- and
hemocompatibility.30 Moreover, PEGylation usually increases
the blood circulation half-life time reducing the detection of
the NPs by the reticuloendothelial system and allows higher
accumulation of NPs at tumor sites. Another functionalization
was carried out on the MSN surface to enable the targeting of
membrane monosaccharide sialic acid (SA) residues, which are
relevant biomarkers of the metastatic activity of tumors.31
To reach this goal we used the bioorthogonal copper-free click
chemistry approach proposed by Bertozzi et al.32,33 based on
metabolic labeling of cell-surface glycans using an azide-
containing analog of acetylated mannose, N-azidoacetyl-D-
mannosamine (Ac4ManNAz). This approach has been widely
applied also in vivo for cancer cell labeling and targeted delivery
of NPs.34–40 Thus, the functionalization of the MSN surface with
a strained cyclooctyne derivative, located at the end terminus of
a long PEG chain, allows exploiting the Cu-free click chemistry
approach in vitro and in vivo by local inoculation of the azido-
modified sugar. The surface of MSNs was also labeled with a
fluorescent dye (rhodamine), in order to enable the visualization
of NPs in the cells. Finally, the chemotherapeutic drug mitoxantrone
(MTX), an anthraquinone derivative that has been extensively
investigated for the treatment of breast and prostate cancer,41 was
confined into the MSN pores. This drug has been chosen as Oupický
et al. have recently demonstrated the efficient loading and release of
this water-soluble weak electrolyte drug into amino- and thiol-
surface modified MSNs.42 In the present work, the properties of
each functionality (the contrast efficiency, the modulation of the
drug release and the particle uptake in malignant tissues) have
been evaluated in detail.
2. Results and discussion
2.1. Synthesis and physico-chemical characterization
A schematic illustration of the multifunctional nanotheranostic
probe is shown in Fig. 1. The first synthetic step was the preparation
of the organo-modified mesoporous silica containing aminopropyl
groups exposed on the surface. The synthesis was carried out
following the traditional sol–gel procedure assisted by the presence
Fig. 1 A schematic illustration and HRTEM micrograph of the theranostic
probe (MTX-Gd-CyPEG-MSN).
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of Pluronic F127 and the cationic surfactant hexadecyltrimethyl-
ammonium chloride (CTAC). The amino groups were introduced
via a one-pot approach during the gel preparation, using amino-
propyltriethoxysilane as the precursor. As indicated by high-
resolution TEM micrographs, such a synthetic procedure allowed
us to obtain particles with size below 100 nm, in agreement with
MSNs prepared by a similar approach (Fig. 1).22 Moreover, the
TEM images indicate the presence of a regular porosity along the
entire spheroidal nanoparticle. Further details on the physico-
chemical properties of these porous nanoparticles have been
described previously.21,22
The cyclooctyne-PEG (Cy-PEG, Scheme S3, ESI†) derivative was
synthesized in two steps by reacting azadibenzo-cyclooctynamine
with Mal-PEG3000-NHS followed by Michael addition of mercapto-
propionic acid to the terminal maleimide. The surface functionali-
zation of the organo-modified MSN with GdDOTAGA and
Cy-PEG3000 molecules was carried out by reacting the in situ
activated carboxylic acid groups to the NH2 groups present on
the silica surface (Gd-CyPEG-MSN). A reference sample prepared
in a similar way but containing non-functionalized PEG3000 was
also synthesized (hereafter named Gd-PEG-MSN). The surface of
the two MSN samples was finally labeled with rhodamine B
isothiocyanate, which formed a thiourea bond with the amino
functionalities of the organo-modified silica. The average amount
of Gd3+ chelates attached to the surface, estimated by ICP-AES
elemental analysis, was 22 (22 650 Gd3+ ions per particle) and 44
mmol g1 (45 300 Gd3+ ions per particle) for Gd-CyPEG-MSN and
Gd-PEG-MSN samples, respectively (Table 1). The loading of the
dye present in both NPs was estimated by UV/Vis spectroscopy.
Spectroscopic data indicate that 0.12 and 0.32 mmol g1 of
fluorophore are attached to Gd-CyPEG-MSN and Gd-PEG-MSN,
respectively (Fig. S1, ESI† and Table 1). The cyclooctyne-PEG
moiety in the Gd-CyPEG-MSN sample was also quantified by
UV–visible titration with a cyanine dye containing an azide group
(Cy5.5-azide, Scheme S1, ESI†) that can react by a Cu(I)-free click
chemistry reaction with the cyclooctyne group. Using this method
we determined the excess amount of Cy5.5-azide that remained
in the liquid phase after reaction in water with the CyPEG derivative
attached to the silica surface (Fig. S2, ESI†), by analyzing the visible
absorption band of cyanine at 675 nm. The amount of azadibenzo-
cyclooctyne molecules was estimated to be 50 mmol g1 (Table 1).
The behavior of the functionalized samples in aqueous solutions
appeared markedly different with respect to the unmodified MSNs.
For the latter, we observed a heterogeneous particle size distribution
(determined by DLS analysis) centered at 180 nm. In contrast, for
both Gd-CyPEG-MSN and Gd-PEG-MSN samples the hydrodynamic
radius distribution appeared narrow with a maximum value of
110 nm (Fig. 2). In addition, we improved the suspension
stability over time, which remained substantially constant for
ca. 10 days (Fig. 2B). These results can be attributed to the presence
of PEG molecules on the particle surface that improves the solubility
and prevents aggregation. Moreover, the functionalized silica
particles showed a slightly positive charge density (zeta-potential) of
+2.0  0.5 mV, exposed on the surface, due to the presence of
residual non-functionalized NH3
+ groups.
The electronic properties of both dye-functionalized NPs
were investigated by UV/Vis and photoluminescence (PL) spectro-
scopy (Fig. S3, ESI†). The UV/Vis spectrum of rhodamine in water
shows absorption maxima attributed to the p - p* transitions
(l = 525 and 557 nm); the same bands are observed after
conjugation of the dye to MSNs. Moreover, the PL spectra of
both rhodamine and dye-functionalized MSNs, recorded in
aqueous solution, display an emission band with a maximum
at 580 nm (Fig. S3, ESI†).
2.2. 1H NMR relaxometric characterization
The 1H NMR relaxometric properties of Gd-CyPEG-MSN and
Gd-PEG-MSN were investigated in aqueous solution at neutral
pH and 298 K to evaluate the efficacy of the theranostic probe as
an imaging reporter. The efficacy of an MRI contrast agent can
be determined by the longitudinal relaxivity parameter (r1) that
corresponds to the variation in the relaxation rates of water
protons normalized to 1 mM concentration of the paramagnetic
probe. The r1 values at 0.47 T (20 MHz) for Gd-CyPEG-MSN
and Gd-PEG-MSN are 49.2 (r1 E 1.1  106 per particle) and
45.7 mM1 s1 (r1 E 2.1  106 per particle), respectively. These
values are ca. 10 times higher than that of the discrete GdDOTAGA
complex, in agreement with the results reported previously on
MSN samples selectively functionalized on the external surface
with the same Gd chelates.21 These values are sensibly higher
(more than 50%) than those measured for other theranostic
Gd-based systems in which the Gd-complex anchored onto the silica
surface was a GdDOTA-monoamide27 or GdDTPA-monoamide.28
This result confirms the importance of anchoring onto the silica
surface an anionic GdDOTA-like complex, such as GdDOTAGA,
Table 1 Quantification of the organic functionalities confined in different samples
[Gd3+]/mmol g1 [Rhodam]/mmol g1 [CyOct]/mmol g1 [MTX]/mmol g1
Gd-PEG-MSN 44 0.32 — —
Gd-CyPEG-MSN 22 0.12 50 —
MTX-Gd-CyPEG-MSN 22 0.12 50 1.6
Fig. 2 (A) DLS analysis at 298 K of MSNs (red), Gd-PEG-MSNs (blue) and
Gd-CyPEG-MSNs (green) in aqueous solution; and (B) stability of the
aqueous suspension of Gd-CyPEG-MSNs over time.
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which presents a faster water exchange rate of the coordinated
water molecule (kex B 7  106 s1) with respect to GdDOTA- or
GdDTPA-monoamides. The other important factor to consider is
the stability of the macrocyclic Gd-complexes anchored onto the
NP surface: GdDOTAGA chelates ensure excellent in vitro and
in vivo stability and an improved safety profile with respect to
transmetallation by endogenous metal ions or transchelation by
endogenous anions.
In particular, it is well-established that high relaxivity values
in the 20–60 MHz (0.5–1.5 T) magnetic field strength range are
related to a restriction of the molecular tumbling motion of the
complex when conjugated to the particle surface.5 Based on
the high r1 values observed for both samples, we hypothesize
that most of the GdDOTAGA complexes are accessible to water
molecules, which are mainly distributed on the external surface.
To get more insight into the molecular parameters affecting r1,
the proton relaxation rate was measured as a function of the
magnetic field strength, from 1.0 to 60 MHz at 298 K, obtaining
a so-called Nuclear Magnetic Relaxation Dispersion (NMRD)
profile. Both Gd-CyPEG-MSN and Gd-PEG-MSN show similar
profiles characterized by the presence of a broad peak with
maximum at 20 MHz, typical of paramagnetic macromolecular
systems with hindered rotation dynamics (Fig. 3).
The physico-chemical parameters of the paramagnetic MSNs
can be determined by analyzing the NMRD profiles according
to well-established theoretical models based on the Solomon–
Bloembergen–Morgan equations.4 For paramagnetic chelates
attached to NPs, the rotational mobility is better analyzed by
following the Lipari–Szabo model free approach. Such a model
distinguishes the rapid local rotation of the complex (tRL) from
the global motion of the entire NP (tRG). The coupling of local
and global motions is defined by the parameter S2 that varies
between 1 (global and local motions coincide) and 0 (local and
global motions are completely independent).43,44 The best-fit
was achieved by fixing the number of water molecules directly
coordinated to the metal ion to 1 (q = 1), the distance between
the metal and protons of the inner sphere water molecule (rGdH)
to 3.0 Å and tRG to 0.1 ms in agreement with paramagnetic
MSNs previously reported (Table 2).11–14 The electronic para-
meters (D2 and tV) were introduced in the fitting as empirical
parameters because they do not have a real physical meaning
for nanosized systems.
The parameters that significantly influence the r1 values at
high magnetic fields are tRL, S
2 and the inner sphere water
residence lifetime (tM). The local mobility of the complex in
both samples is restricted owing to the conjugation to the silica
surface. The local rotational correlation time is ca. 1 ns for both
materials, more than two orders of magnitude higher with respect
to the re-orientational correlation time of the free complex. The
value of S2 around 0.4 confirms the restricted mobility of the
complexes around the linker to the NP.5 The mean residence
lifetime of the coordinated water molecule was 124 and 162 ns
for Gd-PEG-MSN and Gd-CyPEG-MSN, respectively, similar to
the values obtained for MSNs functionalized on the external
surface with GdDOTAGA chelates21 and only slightly higher that
that measured for mononuclear GdDOTAGA.29
2.3. Drug loading and release
The theranostic agent was finally prepared by impregnating
Gd-CyPEG-MSNs with the chemotherapeutic drug mitoxantrone
(MTX-Gd-CyPEG-MSN). Mitoxantrone is a DNA intercalating
drug that inhibits DNA duplication and transcription, and is
used for the treatment of breast cancer, lymphoma and leukaemia.
This step was carried out in water at room temperature for 24 h. The
amount of drug in the MSNs was 1.6 mmol g1 (ca. 0.7 mg g1),
as determined by fluorescence spectroscopy (Fig. S4, ESI†). This
amount is lower than that observed in non-functionalized
MSNs,42 clearly due to the presence of multiple entities on the
surface of NPs (Gd-complexes, rhodamine and PEG molecules)
that hinders access to the pores. The release of MTX from NPs
was assessed at 37 1C under dialysis. The MTX showed an initial
rapid release of about 60% of the total drug within the first
3 hours, followed by a slower and continuous release (Fig. 4), in
agreement with the data already reported in the literature for
non-functionalized MSNs.42 The high initial burst release can be
attributed to the dissolution of MTX physically adhered to the
surface or located in the first layers of the solid NPs.
2.4. Evaluation of the efficiency of bio-orthogonal labeling
with ADIBO-FITC
Two mammary cancer cell lines, one human (MCF7) and one
murine (TS/A), were used for the preliminary assessment of the
correct exposure of Ac4ManNAz on the cell surface. To this end,
the cells were incubated in the presence of an Ac4ManNAz
solution (50 mM in 0.25 v/v% ethanol in cell medium) for
Fig. 3 1H NMRD profiles at 298 K of Gd-PEG-MSN (blue) and Gd-CyPEG-
MSN (green) samples. The best-fit curves were calculated using the para-
meters in Table 2.
Table 2 Selected best-fit parameters obtained from the analysis of
1H NMRD profiles of Gd-PEG-MSN and Gd-CyPEG-MSN at 298 Ka
Parameters Gd-PEG-MSN Gd-CyPEG-MSN
20r1 [mM
1 s1] 45.7 49.2
tRG [ms] 0.1 0.1
tRL [ns] 0.99  0.51 1.52  0.47
tM [ns] 124  9 162  5
S2 0.37  0.13 0.45  0.08
a The following parameters were fixed to common values during the
fitting procedure: rGd-H = 3.0 Å, a = 4.0 Å, D = 2.3  105 cm2 s1.
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72 hours at 37 1C (5% CO2). Azide-modified sugars were
incorporated through existing biosynthetic pathways both onto
the cell surface and in internal glycans. After incorporation, the
azide groups were available for reaction with the dye ADIBO-FITC
containing a cyclooctyne moiety (Scheme S2, ESI†).45 The reaction
was carried out by incubating both cell lines for 60 min at 37 1C in
the presence of 60 mM ADIBO-FITC (0.2 v/v% ethanol in cell
medium). Then cell labeling was assessed by measuring the
fluorescence intensity of cell lysates in 0.1% Triton in phosphate
buffer saline (PBS) (Fig. 5A), after extensive washing in PBS.
The amount of FITC that remains bound to the cells was
normalized to the total cell protein content. Fig. 5A shows that the
ADIBO-FITC cell binding is significantly higher in cells pre-incubated
with the Ac4ManNAz sugar and that labeling efficiency is higher in
the case of human MCF7. The next experiments were carried out
only on this cell line. Fig. 5B shows the direct correlation between
ADIBO-FITC concentration used during the incubation and labeling
efficiency. In the range of concentrations considered, the saturation
of Ac4ManNAz residues was not yet reached.
2.5. Labeling of MCF7 with Gd-CyPEG-MSNs
To the best of our knowledge, the bio-orthogonal targeting
strategy has not yet been used with functionalized MSNs. In
fact, Chiu et al. reported the preparation and characterization
of cyclooctyne-modified MSNs in which the Cu(I)-free click
chemistry approach was used for conjugation of a dye molecule
to the MSN surface, and not for cellular targeting.46
Using the same experimental protocol discussed above,
0.5 million MCF7 were incubated in the presence of Gd-CyPEG-
MSNs directly re-suspended in the cell medium. In fact, the
presence of 10% serum concentration reduces the nanoparticle
aggregation and the average Gd-CyPEG-MSN diameter remains
at ca. 120 nm for about 20 min. For this reason, a very short
incubation time (10 min at room temperature), sufficient for the
bioorthogonal reaction,47 was used to avoid Gd-CyPEG-MSN
aggregation over time. In fact, the azadibenzocyclooctyne moieties
on the nanoprobe’s surface were chosen as they are reported to
undergo a fast click reaction with azides47 also under in vivo
conditions. Fig. 6 shows that after 10 min incubation at room
temperature, similar amounts of NPs (measured by rhodamine
fluorescence and Gd measurements by ICP-MS) are taken-up by
the MCF7 cells, either pre-incubated or not with Ac4ManNAz.
As possible explanations, the cyclooctyne group was not
sufficiently available for the reaction with the azide group on the
cell membrane (likely because of its folding towards the MSN
surface) or simply the background signal generated by the extremely
fast non-specific MSNs binding covered the specific one, even when
using PEG-coated MSNs. Indeed, the few examples of successful
bioorthogonal two step labeling strategies based on nanosized
probes were performed by using NPs with a lower unspecific affinity
for the cell surface (glycol chitosan NPs or liposomes).34,35,39
Another possibility is related to the hydrophobic nature of
the dibenzocyclooctyne that could make it less available for
targeting. Therefore, the use of bicyclononynes could provide a
good balance in terms of reactivity and hydrophilicity, thus
improving the targeting efficiency.48,49
The unspecific affinity of Gd-CyPEG-MSNs for the cell surface
was confirmed by MRI analysis of T1-weighted images. As shown
in Fig. 7, although a strong signal enhancement (ca. 200%) was
observed with respect to untreated cells, the pre-incubation with
Ac4ManNAz does not affect the signal intensity of cell pellets and
their corresponding R1 measured at 7 T. This result confirms that
the high relaxivity showed by Gd-complexes conjugated to the
MSN external surface allowed the observation of a remarkable
contrast even when the cells were incubated with the MSNs for a
few minutes.
Fig. 4 In vitro MTX release from MTX-Gd-CyPEG-MSNs evaluated at
different times (3, 24, and 48 h) under dialysis in water at 37 1C. The bars
show the mean SE of % MTX release obtained from three independent
experiments.
Fig. 5 Spectrofluorimetric analysis of (A) MCF7 and TS/A cells labeled with
60 mM ADIBO-FITC pre-incubated in the presence or in the absence of
Ac4ManNAz and (B) MCF7 cells labeled with 6–60 mM ADIBO-FITC pre-
incubated in the presence or in the absence of Ac4ManNAz. Fluorescence
values measured for cell lysates (upon treatment with 0.1% Triton) were
normalized to the total cell protein content determined by Bradford assay.
Error bars correspond to SE. * p o 0.05. ** p o 0.01. Student t-test.
Fig. 6 Spectrofluorimetric (A) and ICP-MS (B) analysis of MCF7 cells
labeled with Gd-CyPEG-MSNs (20–150 mM Gd) pre-incubated in the
presence or in the absence of Ac4ManNAz. The amount of rhodamine
and Gd measured for cell lysates was normalized to the total cell protein
content determined by Bradford assay. Error bars correspond to SE.




















































J. Mater. Chem. B This journal is©The Royal Society of Chemistry 2019
2.6. Cytotoxicity test of MSNs embedded with MTX
(MTX-Gd-CyPEG-MSNs)
MCF7 cell vitality was determined by the MTT assay. The cells
were incubated for 10 min in the presence of MTX-Gd-CyPEG-
MSNs and MTX alone, at a 1–12.5 mM concentration range.
After washing, the cells were left 24 h in a fresh medium before
MTT. MTX toxicity was evaluated for both cells pre-incubated
and not pre-incubated with Ac4ManNAz for 72 h. Fig. 8A shows
that the toxicity of MTX loaded in MSNs is significantly higher
than that observed with MTX incubated alone at the same
concentration. In fact, 10 min is a short incubation time and
the amount of MTX internalized, when incubated alone, is not
sufficient to induce a significant cell toxicity and the vitality
remains 460% also at high MTX concentrations (12.5 mM)
(Fig. 8A). Instead, delivery of MSNs significantly increased the
rate of MTX internalization due to their affinity for the cell
surface. As a result, cell vitality decreased to less than 40% at
high MTX concentrations. Cell vitality was not significantly
different in cultures pre-incubated or not with Ac4ManNAz,
confirming that MSNs do not increase the amount of MTX
delivered through the binding to the azide group on the
sugar moiety. Furthermore, the amount of MTX found asso-
ciated with cells was determined after 10 min incubation of
MTX-Gd-CyPEG-MSNs. This was extrapolated by ICP-MS Gd
concentration measurements using the ratio Gd/MTX = 12 found
in naked NPs. The same amount of pure MTX was added to the
culture medium to test its cytotoxicity in MCF7 cells. Data in
Fig. 8B show that MTX released by MSNs elicits a cytotoxic effect
higher than that of free MTX administered at the same ratio,
supporting the conclusion that theranostics is more efficient in




pentanedioic acid = DOTAGA was purchased from Chematech
(France). Mitoxantrone was purchased from 3V Chimica S.r.l.
(Italy). Mal-PEG3000-NHS and azadibenzocyclooctinamine were
purchased from Iris Biotech GmbH (Germany). Cy5.5-azide
(Scheme S1, ESI†) was purchased from Lumiprobe GmbH.
ADIBO-FITC (Scheme S2, ESI†) and Ac4ManNAz were synthe-
sized as reported previously.45 All other materials and solvents
were purchased from Sigma-Aldrich and used without further
purification.
3.2. Synthesis
GdDOTAGA. The Gd(III) complex was prepared by adding an
equimolar amount of GdCl3 solution to the ligand solution in
water, maintaining the pH at 6.5 with diluted sodium hydroxide.
The solution was stirred overnight at 298 K and the pH was
corrected to 9 in order to promote the precipitation of unreacted
Gd3+ as Gd(OH)3. The suspension was then centrifuged at 4000 rpm
for 5 min and the solution was filtered using 0.2 mm filters. Finally,
the solvent was removed under reduced pressure leading to the
formation of a white solid. ESI-MS: m/z calcd for the complex
(C19H27GdN4O10): 628.7; found: 628.5 [M H+]. The peak attributed
to the Gd(III)-complex showed the correct isotopic distribution.
Cy-PEG-Mal (Scheme S3a, ESI†). Mal-PEG3000-NHS (50 mg)
was dissolved in DCM (7 mL). Azadibenzocyclooctinamine
(6 mg) was added to the solution, and the mixture was stirred
at room temperature overnight. The resulting solution was
poured into an excess of Et2O (30) and the obtained suspension
was centrifuged (4000 rpm, 30 min, 10 1C). The supernatant was
discarded and the remaining solid was washed/centrifuged with
Et2O (3  10 mL) and dried under vacuum. The product (white
solid, 41 mg) was used without further purification (Fig. S5a,
ESI†). 1H NMR (CDCl3, 500 MHz, 25 1C): 7.38 (m, 8H), 6.69
(s, 2H), 6.54 (bs, 1H), 6.09 (bs, 1H), 5.15 (d, 1H), 3.8–3.4 (m, xH),
3.30 (m, 2H), 2.47 (m, 1H), 2.32 (m, 2H), 2.16 (m, 2H), 1.98 (m,
1H), 1.63 (m, 4H), and 1.31 (m, 2H). 13C NMR (CDCl3, 125 MHz,
25 1C): 172.8 (CO), 172.0 (CO), 171.1 (CO), 170.9 (CO), 151.1 (CAr),
148.1 (CAr), 134.1 (CHMal), 132–114 (CHAr + CAr), 109.3 (CC),
107.8 (CC), 71–65 (OCH2), 55.5 (CH2
CyOct), 39.2 (NCH2),
37.1 (NHCH2), 37.7 (NHCH2), 36.4 (COCH2), 35.2 (COCH2),
34.8 (COCH2), 28.4 (CH2), 26.5 (CH2), and 25.2 (CH2).
Fig. 7 T1-weighted MRI image (A), % SI enhancements (B) and longitudinal
relaxation rates R1 (C); analyses of an agar phantom containing glass
capillaries with MCF7 cell pellets: untreated cells (1) and cells previously
labeled with Gd-Cy-PEG-MSNs pre-incubated either in the absence (2) or
the presence (3) of Ac4ManNAz. Error bars correspond to SE.
Fig. 8 Cytotoxicity assay (MTT) of Gd-CyPEG-MSNs embedded with MTX
(Gd-MTX-CyPEG-MSNs). Error bars correspond to SE. *** p o 0.001,
Student t-test.
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Cy-PEG-COOH (Scheme S3b, ESI†). Mal-PEG3000-CyOct
(40 mg) was dissolved in DCM (5 mL) and mercaptopropionic acid
(4 mL) was added. The solution was stirred at room temperature
overnight and poured into an excess of Et2O (30). The resulting
precipitate was centrifuged (4000 rpm, 30 min, 10 1C) and washed/
centrifuged with Et2O (3  10 mL). After drying under vacuum, a
white solid (38 mg) was obtained, which was used without further
purification (Fig. S5b, ESI†). 1H NMR (CDCl3, 500 MHz, 25 1C): 7.3–
7.0 (m, 8H, Ar), 6.66 (bs, 1H, m), 6.62 (bs, 1H, g), 4.62 (d, 1H), 3.76
(CHS), 3.7–3.4 (m, [OCH2CH2O]n), 2.92 (m, 2H, CH2CHS), 2.69
(SCH2), 2.52 (CH2COOH), 2.44 (m, 1H), 2.24 (m, 2H), 2.18 (m,
2H), 2.15 (m, 1H), 1.85 (m, 2H), 1.60 (m, 2H), and 1.28 (m, 2H). 13C
NMR (CDCl3, 125 MHz, 25 1C): 177.3 (CO), 175.4 (CO), 174.3 (CO),
172.6 (CO), 142.0 (CAr), 132–128 (CHAr + CAr), CC resonances are
too broad to be observed, 71–65 (OCH2), 54.2 (CH2
CyOct), 40.3 (CHS),
39.9 (NHCH2), 39.4 (NCH2), 37.5 (NHCH2), 36.7 (COCH2), 35.4
(COCH2), 34.9 (CH2COOH), 34.4 (CH2CHS), 33.9 (COCH2), 26.9
(CH2), 26.3 (CH2), 26.1 (CH2), and 25.8 (CHS).
Synthesis of organo-modified MSN nanoparticles. The MSN
nanoparticles were synthesized following the procedure described
in the literature.13 In detail, tetraethoxysilane (TEOS) (3.15 g,
15 mmol) and aminopropyl triethoxysilane (APTS) (0.37 g,
1.7 mmol) were dissolved in 30 g of a diluted hydrochloric acid
solution (0.3 mol L1) at room temperature along with 2.6 g of
cetyltrimethylammonium chloride and 2.0 g of Pluronic F127.
After stirring for 3 h at room temperature, 3.0 g of ammonia
solution (14.7 mol L1) were added to the suspension. The final
gel was stirred at RT for 24 h, transferred to an autoclave at
60 1C for another 24 h and centrifuged at 4000 rpm for 5 min.
The gel was transferred to a dialysis membrane (Sigma Aldrich,
molecular weight cut-off 14 000), and dialyzed in 500 mL acid
solution containing 250 mL of water, 250 mL of ethanol and
5 mL of acetic acid for 24 h in order to remove surfactant
molecules. The procedure was repeated three times and finally
dialysis in 1 L of deionized water for 8 h was also carried out.
Preparation of Gd-CyPEG-MSN and Gd-PEG-MSN. A DMF
suspension (40 mL) containing 200 mg of MSN nanoparticles
was stirred for a few minutes at room temperature. In parallel,
90.7 mg of GdDOTAGA, 106.2 mg of HBTU and 37 mg of HOBT
were dissolved in 5 mL of DMF. After complete dissolution of
the samples, 33 mg of Cy-PEG-COOH and 100 mL of DIPEA were
added. The final solution was added to the MSN suspension
and stirred for 18 h at RT. The suspension was then centrifuged
at 7000 rpm at 10 1C in order to isolate the nanoparticles. In the last
step, the particles were suspended in 40 mL of water containing
300 mL of the rhodamine solution previously prepared by
dissolving 1.24 mg of the dye in 10 mL of water. The suspension
was stirred at RT for 8 h and centrifuged at 7000 rpm for 10 min
at 10 1C. After removal of the solvent, the particles were
resuspended in water. Gd-PEG-MSN was prepared by a similar
procedure.
The Gd loading per particle was determined by assuming a
spherical shape for the particles and a density of 0.8 g cm3 for the
Gd-CyPEG-MSN and Gd-PEG-MSN samples.22 The concentration
of the cyclooctyne group on the silica surface was quantified by
UV–visible titration with a cyanine probe containing an azide
group (Cy5.5-azide, Scheme S1, ESI†). The silica nanoparticles in
aqueous solution were treated with the dye for 15 min and then
centrifuged. The excess amount of Cy5.5-azide that remained in
the liquid phase after the reaction was analysed by UV–visible
spectroscopy by evaluating the absorption band of cyanine at
675 nm (Fig. S2, ESI†).
Impregnation of mitoxantrone in Gd-CyPEG-MSN and drug
release assay. 10 mL of an aqueous suspension containing
50 mg of CyPEG-MSN were stirred for 10 min at room temperature.
14 mg of mitoxantrone were dissolved in the suspension. The
impregnation reaction was maintained by stirring for 24 h at
RT. Finally, the suspension was centrifuged and a blue powder
was isolated.
After MTX-Gd-CyPEG-MSN resuspension in water at a
concentration of 0.2 mM Gd (as by ICP-AES), aliquots of the sample
(200 mL) were centrifuged for 10 min at 7500 rpm and the silica were
resuspended in 2 mL of DMSO in order to determine the MTX
concentration. The concentration of drug was quantified by
measuring the fluorescence intensity according to a MTX calibration
curve (Ex 620 nm Em 692 nm in the range of 0.1–2 mM) using a
spectrofluorimeter HORIBA Jobin Yvon Fluoromax-4, Edison,
NY, USA.
To perform the drug release assay, following the procedure
described above, 1.5 mL of MTX-Cy-PEG-MSNs at a 0.2 mM Gd
concentration in water were dialyzed at 37 1C (MWCO 14 kDa)
in 40 mL water for 48 h. At 0, 3, 24 and 48 h time intervals,
200 mL of the dialyzed MTX-Gd-CyPEG-MSNs were taken and
centrifuged for 10 min at 7500 rpm. Then, after removing the
supernatant buffer, the MTX-Gd-CyPEG-MSNs were resuspended
in 2 mL of DMSO. The 40 mL dialysis solution was renewed at
each drawing. The percentage of MTX released was calculated
using the equation:
%release ¼MTX t0ð Þ MTX tið Þ
MTX t0ð Þ
 100
for which MTX (ti) is the amount of MTX loaded in MTX-Gd-
CyPEG-MSNs measured by spectrofluorimetry at various time
intervals (t = 0, 3, 24, and 48 h), and MTX (t0) is the amount of
MTX loaded in MTX-Gd-CyPEG-MSNs at the starting point (t = 0)
of the drug release test.
3.3. Characterization techniques
The elemental analyses were carried out using a Spectro Genesis
inductively-coupled plasma atomic emission spectrometer equipped
with a cross-flow nebulizer (ICP-AES). Prior to the analyses, the
samples were mineralized by treatment with a mixture of HNO3
(5 mL) and HF (5 mL) at 100 1C for 8 h.
The chromatographic analyses were carried out using a Waters
high-performance liquid chromatography–mass spectrometry sys-
tem equipped with an electrospray ion source (HPLC-MS ESI+/),
a Waters 1525 Binary HPLC pump, a Waters 2489 UV-Vis detector
and a Waters SQD 3100 mass detector. The mass spectra, obtained
through the MS-ESI+/ technique, were recorded using the Waters
SQD 3100 mass detector.
High-resolution transmission electron microscopy (HRTEM)
images were collected using a JEOL 3010 High Resolution
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Transmission Electron Microscope operating at 300 kV. The
specimens were prepared by depositing the samples on carbon-
coated grids.
The UV–vis spectra were recorded at RT in the range 200–
900 nm with a resolution of 1 nm, using a double-beam PerkinElmer
Lambda 900 spectrophotometer.
Dynamic light scattering experiments (DLS) were carried out
at 25 1C by using a Malvern Zetasizer NanoZS operating in the
particle size range from 0.6 nm to 6 mm and equipped with a
He–Ne laser with l = 633 nm.
The water proton longitudinal relaxation rates as a function
of the magnetic field strength were measured in non-deuterated
aqueous solutions using a Fast Field-Cycling Stelar SmarTracer
relaxometer (Stelar s.r.l., Mede (PV), Italy) over a continuum of
magnetic field strengths from 0.00024 to 0.25 T (corresponding
to 0.01–10 MHz proton Larmor frequencies). The relaxometer
operates under computer control with an absolute uncertainty
in 1/T1 of 1%. Additional longitudinal relaxation data in the
range 20–70 MHz were obtained using a Stelar Relaxometer
connected to a Bruker WP80 NMR electromagnet adapted to
variable-field measurements. The 1H T1 relaxation times were
acquired by the standard inversion recovery method with a
typical 901 pulse width of 3.5 ms, 16 experiments of 4 scans.
The temperature was controlled using a Stelar VTC-91 airflow
heater equipped with a calibrated copper-constantan thermo-
couple (uncertainty of 0.1 1C). The concentration of Gd3+ ions
for each analysed suspension was measured by 1H NMR (500 MHz)
experiments using the Evans method.50
3.4. Biological analyses
Human MCF7 breast cancer cell line was purchased from
American Type Culture Collection (ATCC, USA) and murine TS/A
breast cancer cell line was kindly provided by Prof. F. Cavallo’s
group, University of Turin. The MCF7 cells were cultured in EMEM
(Lonza) supplemented with 10% (v/v) fetal bovine serum (FBS),
2 mM glutamine, 100 U mL1 penicillin, 100 U mL1 strepto-
mycin, 1 mM sodium pyruvate, non-essential amino acids, and
10 mg mL1 insulin (Sigma). The TS/A cells were cultured in
RPMI (Lonza) supplemented with 10% (v/v) FBS, 4 mM glutamine,
100 U mL1 penicillin and 100 U mL1 streptomycin.
For ADIBO-FITC labelling experiments, 2.5  105 MCF7 and
TS/A cells were seeded in 6 cm diameter Petri dishes. After 24 h,
they were incubated in the absence or in the presence of 50 mM
Ac4ManNAz (0.25 v/v% ethanol in medium, Lonza) for 72 h at
37 1C and 5% CO2. After the incubation, the cells were washed
three times with phosphate buffer saline (PBS) and incubated
for another 1 h at 37 1C and 5% CO2 in the presence of different
concentrations (6–60 mM) of ADIBO-FITC (0.2 v/v% ethanol in
medium). Then, the cells were washed three times with PBS,
detached using 1 mM EDTA (ethylenediaminetetraacetic acid),
resuspended in 250 mL of PBS, sonicated in ice at 30% power for
30 s and assayed for their protein content by the Bradford
method. Then, the samples were diluted 1 : 10 in 0.1% Triton
in PBS and analyzed for their FITC fluorescence according to
a FITC calibration curve (Ex 492 nm Em 517 nm in the range
0.5–30 nM). The obtained nanomoles of FITC calculated for
each cell sample were normalized to milligrams of total cell
proteins measured by Bradford assay.
For Gd-CyPEG-MSN uptake experiments, 9  104 MCF7 cells
were seeded in 6 well plates. After 24 h, they were incubated in
the absence or in the presence of 50 mM Ac4ManNAz for 72 h at
37 1C and 5% CO2. After the incubation, they were washed three
times with PBS and incubated for another 10 minutes at room
temperature (RT) in the presence of different concentrations of
Gd-CyPEG-MSNs (20–150 mM Gd). Then, the cells were washed
three times with PBS, detached using 1 mM EDTA, re-suspended
in 200 mL of PBS, sonicated in ice at 30% power for 30 s and
assayed for their protein content by the Bradford method. Then,
the samples were diluted in Triton (0.1% final concentration)
and analysed for their fluorescence by a Promega Glomax-Multi +
Detection System according to a rhodamine B calibration curve
(Ex 525 nm Em 580–640 nm in the range 5–200 nM). The
obtained nanomoles of rhodamine B calculated for each cell
sample were normalized to milligrams of total cell proteins
measured by Bradford assay. Finally, after fluorescence analysis,
the Gd amount in each cell sample was evaluated by ICP-MS.
Digestion was performed by heating under microwave (Mile-
stone Ethos Up Microwave Digestion System) 0.2 mL of cell
suspensions for 200 at 160 1C, after the addition of 0.2 mL of
concentrated HNO3 (70%). After mineralization, 3 mL of ultra-
pure water were added to the remaining sample volumes for
inductively coupled plasma mass spectrometry (ICP-MS; element-2;
Thermo-Finnigan, Rodano (MI), Italy).
MRI studies. According to the above mentioned protocol for
Gd-CyPEG-MSN uptake experiments, about 5  105 MCF7 cells
treated or not treated with Ac4ManNAz, incubated with Gd-CyPEG-
MSNs for 10 minutes at RT (150 mM Gd), were transferred to glass
capillaries placed in an agar phantom. The MR images were
obtained using a standard T1-weighted multi slice spin echo
sequence (TR (repetition time)/TE (echo time)/NEX number of
excitations) = 250/3.7/6, FOV (field of view) = 1.2 cm) connected
to a Bruker Avance300 spectrometer (7 T) provided with a Micro
2.5 microimaging probe (Bruker BioSpin, Ettlingen, Germany).
1/T1 relaxation rates were determined using a standard Saturation
Recovery Spin Echo.
The mean signal intensity (SI) values were calculated in the
regions of interest (ROI) drawn on T1 weighted images of the
cell pellet samples. The mean SI enhancement (%) of cells treated
with Gd-CyPEG-MSN was calculated according to the following
equation: SI% enhancement = ((mean SI (treated cells)  mean SI
(untreated cells)/mean SI (untreated cells))  100.
MTT assay. The MTT assay is based on the reduction of
tetrazolium salts to formazan using mitochondrial succinate
dehydrogenase, which is quantified by a spectrophotometer.
MCF7 cells were seeded at a density of 5  103 cells per well in a
96-well microtiter plate and treated in the presence or in the
absence of 50 mM Ac4ManNAz for 72 h, and after washing with
PBS the cells were incubated with MTX-Gd-CyPEG-MSNs or
with free MTX for 10 minutes at RT (3.3–12.5 mM MTX). After
this time, the incubation medium was removed and renewed
with a 100 mL of fresh medium for another 24 h. Then, this
medium was removed and each well was incubated with thiazolyl
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blue tetrazolium bromide dissolved in the medium at a concen-
tration of 0.45 mg mL1 for 4 h at 37 1C and 5% CO2. Then, after
medium elimination, 150 mL of DMSO were added into each well
to solubilize the formazan salt crystals produced by the meta-
bolism of live cells and the microplate was incubated at room
temperature for 30 min. Finally, absorbance was measured at
570 nm using an iMark microplate reader (Biorad). Cell vitality
was reported as the percentage of dead cells observed in the
treated samples relative to that observed in the non-treated
control cells. Moreover, to assess the cytotoxic effect of free MTX
incubated for a longer time, the same amount of MTX found
associated with cells after 100 incubation with MTX-Gd-CyPEG-
MSNs was incubated alone for 24 h in the cell medium and then
MTT was performed. The amount of MTX internalized by MTX-
Gd-CyPEG-MSNs after 10 min incubation was extrapolated by
the amount of cell internalized Gd measured by ICP-MS (see
above), using the calculated Gd/MTX molar ratio in MSN of 12.
In this way, it was estimated that upon incubation of MTX-Gd-
CyPEG-MSNs at 3.3 and 12.5 mM MTX concentration (10 min at RT),
1.5  104 nmoles and 1  103 nmoles of MTX were taken up by
the cells, respectively.
4. Conclusions
This work describes the development and characterization of
MRI-based theranostic MSNs as biocompatible nanocarriers
that simultaneously display improved physical–chemical properties
and multiple functions including: (i) good chemical stability and
versatility, (ii) high surface area and tunable pore size, (iii) great
potential for anchoring several different chemical entities, (iv) good
dispersibility, (v) high loading of MRI contrast agents, (vi) high
contrast efficiency (high relaxivity), (vii) good delivery of poorly
water-soluble drugs, and (viii) optimized drug biodistribution
through targeted delivery of therapeutics.
In detail, the points (i–iii) include properties that are typical
of MSNs and that have pushed their development in the bio-
medical field in recent years. The other properties were imple-
mented by a multifunctional MSN probe that is equipped with:
(1) thermodynamically stable and kinetically inert Gd-complexes
allowing high relaxivity, (2) PEG molecules that increase the
aqueous solubility of the NPs (which might increase the half-
time in blood circulation), (3) rhodamine molecules for the
spectrofluorimetric analysis of the cellular uptake and localization
of MSNs, and (4) a PEGylated cyclooctyne group that permits the
targeting of membrane monosaccharide sialic acid (SA) residues via
the bioorthogonal Cu(I)-free click chemistry approach. The synthetic
procedure for the multi-functionalization of the MSN platform was
carefully designed in order to obtain the best performance of any
single function. As a result, the multifunctional probe Gd-CyPEG-
MSN shows a very high relaxivity per Gd ion (49.2 mM1 s1),
which is found to be a relaxivity per particle of more than
1.1  106 mM1 s1.
Despite the efficient metabolic azido labeling of the MCF7
and TS/A cell surface, Gd-CyPEG-MSN bioorthogonal binding
was negligible and no significant difference between the MCF7
cells metabolically labeled or not with azido-mannose was
observed. However, our results show that the (unspecific) affinity
of the nanoprobe for the cell surface is sufficient for the successful
delivery of an anticancer drug (such as the MTX used here),
eliciting a cytotoxic effect higher than that obtained with the same
concentration of free drug. Moreover, the high relaxivity showed by
Gd-complexes conjugated to the MSNs enabled us to obtain a
significant contrast enhancement even after very short incubation
times. Thus, in conclusion, we have developed an efficient ther-
anostic nanosystem in terms of diagnostic capability and drug
release efficacy that could be used either to exploit the enhanced
permeability retention effect without the use of a targeting
moiety or in targeted theranostics by changing or improving
the targeting ability.
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